Suppr超能文献

参仙升脉口服液通过AKT/mTOR通路诱导成纤维细胞自噬以减轻病态窦房结综合征小鼠的窦房结纤维化。

Shenxian-Shengmai Oral Liquid Evoke Autophagy of Fibroblast to Attenuate Sinoatrial Node Fibrosis in Sick Sinus Syndrome Mice via the AKT/mTOR Pathway.

作者信息

Chen Chen, Zhang Heng, Hou Siyi, Liu Yue, Ren Lu, Hao Miao, Chen Keyan, Li Lingkang, Cai Xintong, Deng Zisu, Liu Zhuang, Hou Ping

机构信息

Liaoning University of Traditional Chinese Medicine, Shenyang, China.

Department of Cardiology, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, China.

出版信息

Evid Based Complement Alternat Med. 2022 Sep 28;2022:5219277. doi: 10.1155/2022/5219277. eCollection 2022.

Abstract

Sick sinus syndrome (SSS) is closely associated with cardiac syncope and sudden death, wherein sinoatrial node (SAN) fibrosis is one of the main pathological changes that occur. Shenxian-Shengmai oral liquid (SXSM) has been clinically proven to significantly improve the heart rate of SSS patients. In this study, we aimed to explore the mechanism of SXSM in reducing the SAN fibrosis by combining and experiments. Accordingly, the SSS model was constructed by slowly pumping angiotensin II (AngII) with a micro-osmotic pump. The degree of fibrosis was evaluated by Masson's trichrome staining and immunofluorescence staining of the fibrosis marker protein. In addition, NIH-3T3 mouse fibroblasts were used to simulate SAN fibroblasts to further explore the mechanism, with AngII used as the cellular fibrosis inducer. Monodansylcadaverine (MDC) staining and transmission electron microscopy were employed to assay the autophagy content, whereas immunofluorescence staining and Western blotting were employed to elucidate the related protein expression. Finally, fibroblasts were given the AKT phosphorylation agonist SC79 to reversely verify the effects of SXSM. The results showed that SXSM could significantly increase the heart rate of SSS mice by reducing the deposition of extracellular matrix (ECM) in SAN induced by AngII. According to experiments, when compared with the model group, SSS mice treated with SXSM developed less fibrosis in the SAN area. experiments revealed that AngII could restrain autophagy by activating the phosphorylation of the AKT/mTOR pathway, thereby increasing the deposition of ECM. Moreover, SXSM pretreatment prevented this upregulation. After the intervention of SC79, the protective effect of SXSM was weakened. In conclusion, SXSM activated autophagy through the AKT/mTOR pathway, which in turn reduced the deposition of the ECM in SAN induced by AngII, attenuated the fibrosis of SAN, and improved the decreased heart rate in the SSS mice.

摘要

病态窦房结综合征(SSS)与心脏性晕厥和猝死密切相关,其中窦房结(SAN)纤维化是主要的病理变化之一。参仙升脉口服液(SXSM)已在临床上被证明能显著提高SSS患者的心率。在本研究中,我们旨在通过结合体内和体外实验来探索SXSM减轻SAN纤维化的机制。因此,通过微量渗透泵缓慢输注血管紧张素II(AngII)构建SSS模型。通过Masson三色染色和纤维化标记蛋白的免疫荧光染色评估纤维化程度。此外,使用NIH-3T3小鼠成纤维细胞模拟SAN成纤维细胞以进一步探索机制,将AngII用作细胞纤维化诱导剂。采用单丹磺酰尸胺(MDC)染色和透射电子显微镜检测自噬含量,而免疫荧光染色和蛋白质印迹法用于阐明相关蛋白表达。最后,给予成纤维细胞AKT磷酸化激动剂SC79以反向验证SXSM的作用。结果表明,SXSM可通过减少AngII诱导的SAN中细胞外基质(ECM)的沉积来显著提高SSS小鼠的心率。根据体内实验,与模型组相比,用SXSM治疗的SSS小鼠在SAN区域的纤维化程度较轻。体外实验表明,AngII可通过激活AKT/mTOR途径的磷酸化来抑制自噬,从而增加ECM的沉积。此外,SXSM预处理可防止这种上调。在SC79干预后,SXSM的保护作用减弱。总之,SXSM通过AKT/mTOR途径激活自噬,进而减少AngII诱导的SAN中ECM的沉积,减轻SAN的纤维化,并改善SSS小鼠降低的心率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/54a1/9534627/2697cf7a15d3/ECAM2022-5219277.001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验